Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 2/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | QPCT | Q16769 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.38 |
| ▸ | CYP2J2 | P51589 | 3/20 | 0.38 |
| ▸ | HSD17B13 | Q7Z5P4 | 4/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2779357 | 0.85 | HPGD (0.46) | HDAC1 | |
| SCHEMBL2781461 | 0.84 | NTRK1 (0.41) | NTRK1HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL2782657 | 0.83 | LMNA (0.43) | MAPK1 | |
| SCHEMBL2782839 | 0.82 | TAS1R3 (0.42) | RIPK1 | |
| Acetic Acid SCHEMBL2780449 | 0.79 | NTRK1 (0.45) | NTRK1HDAC3HDAC1HDAC2HDAC6 | |
| Acetic Acid SCHEMBL2781661 | 0.78 | LMNA (0.44) | MAPK1 | |
| SCHEMBL2781310 | 0.76 | NTRK1 (0.48) | NTRK1HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL2779421 | 0.76 | GRIN2B (0.47) | NTRK1HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL2784450 | 0.75 | EPHB4 (0.46) | — | |
| SCHEMBL2779634 | 0.75 | RXFP1 (0.40) | HDAC3HDAC1HDAC2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296697-B2 | Hetaryl-substituted guanidine compounds and use thereof as binding partners for 5-HT5-receptors | ABBOTT LABORATORIES (US) | 2016-03-29 | — | — | US | disclosed |
| US-20100184787-A1 | Heataryl-substituted guanidine compounds and use thereof as binding partners for 5-ht5-receptors | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184787-A1 | Heataryl-substituted guanidine compounds and use thereof as binding partners for 5-ht5-receptors | HTR5A, HTR2C, HTR1E | NTRK1 228/4885HDAC3 4618/4885HDAC1 4353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.